OverviewSuggest Edit

Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders. The Company launched Oxtellar XR and Trokendi XR, two novel neurology products for the treatment of epilepsy.  Supernus Pharmaceuticals is also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder and its coexisting disorders, and depression.

TypePublic
Founded2005
HQRockville, MD, US
Websitesupernus.com
Employee Ratings3.2
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2018)448(+7%)
Job Openings47
Revenue (FY, 2020)$520.4 M(+33%)
Share Price (Jun 2021)$31.2(-1%)
Cybersecurity ratingCMore

Key People/Management at Supernus Pharmaceuticals

Jack Khattar

Jack Khattar

President and CEO

Supernus Pharmaceuticals Office Locations

Supernus Pharmaceuticals has an office in Rockville
Rockville, MD, US (HQ)
1550 E Gude Dr
Show all (1)

Supernus Pharmaceuticals Financials and Metrics

Supernus Pharmaceuticals Revenue

Supernus Pharmaceuticals's revenue was reported to be $520.4 m in FY, 2020
USD

Revenue (FY, 2020)

520.4m

Gross profit (FY, 2020)

467.9m

Gross profit margin (FY, 2020), %

89.9%

Net income (FY, 2020)

127.0m

EBIT (FY, 2020)

173.7m

Market capitalization (11-Jun-2021)

1.7b

Closing stock price (11-Jun-2021)

31.2

Cash (30-Sept-2020)

204.3m

EV

1.9b
Supernus Pharmaceuticals's current market capitalization is $1.7 b.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.5m11.6m89.6m143.5m210.1m294.1m408.9m392.8m520.4m

Revenue growth, %

915%18%49%

Cost of goods sold

1.1m5.8m8.4m12.0m15.2m15.4m16.7m52.5m

Gross profit

10.4m83.8m135.1m198.1m278.9m393.5m376.1m467.9m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

208.0k91.0k91.0k147.0k154.0k1.1m9.0m27.6m22.5m28.1m34.3m38.6m43.0m50.3m55.6m56.4m73.3m78.1m90.4m99.5m103.0m85.5m104.7m102.1m95.0m124.0m152.1m

Cost of goods sold

4.0k33.0k494.0k1.7m1.3m1.6m1.8m2.2m2.0m2.8m3.4m2.9m3.9m4.3m3.3m3.7m4.2m3.7m4.0m4.8m4.2m

Gross profit

150.0k1.1m8.5m25.9m21.1m26.5m32.5m36.3m41.0m47.6m52.2m53.4m69.5m73.8m87.2m95.9m98.8m81.8m100.7m97.3m90.8m

Gross profit Margin, %

97%97%95%94%94%94%95%94%95%95%94%95%95%95%96%96%96%96%96%95%96%
USDQ1, 2012

Financial Leverage

157.7 x
Show all financial metrics

Supernus Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
Biscayne NeurotherapeuticsSeptember 17, 2018$193 m

Supernus Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

C

74/100

SecurityScorecard logo

Supernus Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Supernus Pharmaceuticals Online and Social Media Presence

Embed Graph

Supernus Pharmaceuticals Company Culture

  • Overall Culture

    A+

    84/100

  • CEO Rating

    A+

    80/100

  • Compensation

    B

    77/100

Learn more on Comparably

Supernus Pharmaceuticals News and Updates

Thinking about buying stock in Ocugen, Kopin Corp, Mogo Inc, Supernus Pharmaceuticals, or eMagin Corp?

NEW YORK, Dec. 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCGN, KOPN, MOGO, SUPN, and EMAN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

NEW YORK, Nov. 11, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus or the "Company") (NASDAQ: SUPN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980....

Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer

Greg Patrick to Retire as Chief Financial Officer Greg Patrick to Retire as Chief Financial Officer

Supernus Pharmaceuticals Frequently Asked Questions

  • When was Supernus Pharmaceuticals founded?

    Supernus Pharmaceuticals was founded in 2005.

  • Who are Supernus Pharmaceuticals key executives?

    Supernus Pharmaceuticals's key executives are Jack Khattar.

  • How many employees does Supernus Pharmaceuticals have?

    Supernus Pharmaceuticals has 448 employees.

  • What is Supernus Pharmaceuticals revenue?

    Latest Supernus Pharmaceuticals annual revenue is $520.4 m.

  • What is Supernus Pharmaceuticals revenue per employee?

    Latest Supernus Pharmaceuticals revenue per employee is $1.2 m.

  • Who are Supernus Pharmaceuticals competitors?

    Competitors of Supernus Pharmaceuticals include ACADIA Pharmaceuticals, Galecto and Acceleron Pharma.

  • Where is Supernus Pharmaceuticals headquarters?

    Supernus Pharmaceuticals headquarters is located at 1550 E Gude Dr, Rockville.

  • Where are Supernus Pharmaceuticals offices?

    Supernus Pharmaceuticals has an office in Rockville.

  • How many offices does Supernus Pharmaceuticals have?

    Supernus Pharmaceuticals has 1 office.